Sign inCreate account

Report workspace

Add to folder
NCT06747351RECRUITINGanonymous

A Phase 3, Single-Arm, Multiple-Dose, Pharmacokinetic Comparability Trial Between TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Sponsor

Source record

Takeda

Phase

Source record

Phase 3

Modality

AI-normalized

protein therapy

Target

AI-normalized

Immunoglobulin G (IgG) levels modulation via subcutaneous administration of TAK-881 and HYQVIA for the treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP).

Indication / condition

AI-normalized

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Intervention

Source record

TAK-881, HYQVIA, SC Investigational Needle Sets

Related intelligence directories

Indication directory: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)Modality directory: protein therapyTarget directory: Immunoglobulin G (IgG) levels modulation via subcutaneous administration of TAK-881 and HYQVIA for the treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP).

Source & freshness

Source record

NCT ID

NCT06747351

Original source

ClinicalTrials.gov

Source last updated

Jan 20, 2026

Ingested at

Jun 19, 2026

Internal sync

Jun 19, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT06747351

Title

A Phase 3, Single-Arm, Multiple-Dose, Pharmacokinetic Comparability Trial Between TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Sponsor

Takeda

Status

RECRUITING

Phase

Phase 3

Condition raw

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Condition normalized

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Modality raw

protein therapy

Modality normalized

protein therapy

Target raw

Immunoglobulin G (IgG) levels modulation via subcutaneous administration of TAK-881 and HYQVIA for the treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP).

Target normalized

Immunoglobulin G (IgG) levels modulation via subcutaneous administration of TAK-881 and HYQVIA for the treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP).

Interventions

TAK-881, HYQVIA, SC Investigational Needle Sets

Public preview

Source record

Takeda's Phase 3 trial of TAK-881 aims to establish pharmacokinetic comparability with HYQVIA, a current treatment for CIDP. The trial's design allows for a direct comparison of two subcutaneous immunoglobulin therapies, potentially positioning TAK-881 as a competitive alternative in the CIDP market. Given the increasing prevalence of CIDP and the growing demand for effective therapies, successful outcomes could enhance Takeda's market share in the immunoglobulin therapy sector. The trial's recruitment status is currently active, with an estimated enrollment of 59 participants, indicating a focused approach to gathering robust data. The competitive landscape includes existing therapies like HYQVIA and other immunoglobulin products, necessitating a thorough analysis of efficacy and safety profiles to ensure differentiation.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 3, Single-Arm, Multiple-Dose, Pharmacokinetic Comparability Trial Between TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 19, 2026

NCT ID

NCT06747351

Status

RECRUITING

Phase

Phase 3

Sponsor

Takeda

Executive brief

Investment-Ready Snapshot

Takeda's Phase 3 trial of TAK-881 aims to establish pharmacokinetic comparability with HYQVIA, a current treatment for CIDP. The trial's design allows for a direct comparison of two subcutaneous immunoglobulin therapies, potentially positioning TAK-881 as a competitive alternative in the CIDP market. Given the increasing prevalence of CIDP and the growing demand for effective therapies, successful outcomes could enhance Takeda's market share in the immunoglobulin therapy sector. The trial's recruitment status is currently active, with an estimated enrollment of 59 participants, indicating a focused approach to gathering robust data. The competitive landscape includes existing therapies like HYQVIA and other immunoglobulin products, necessitating a thorough analysis of efficacy and safety profiles to ensure differentiation.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJan 20, 2026
Internal syncJun 19, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06747351

Indication

Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Modality

protein therapy

Target

Immunoglobulin G (IgG) levels modulation via subcutaneous administration of TAK-881 and HYQVIA for the treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP).

Intervention

TAK-881, HYQVIA, SC Investigational Needle Sets

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.